Showing results (1111-1120 of 6,495) with videos related to
Sort By:
Pageof 650
Journal of Thrombosis and Haemostasis : JTH|June 1, 2021
Factor XII protects neurons from apoptosis by epidermal and hepatocyte growth factor receptor-dependent mechanismsEugénie Garnier, Damien Levard, Carine Ali, et al.Journal of Thrombosis and Haemostasis : JTH|January 12, 2021
Success and limitations of plasma treatment in pregnant women with congenital thrombotic thrombocytopenic purpuraKazuya Sakai, Yoshihiro Fujimura, Yasuyuki Nagata, et al.Journal of Thrombosis and Haemostasis : JTH|June 23, 2021
Platelet activation and aggregation response to dengue virus nonstructural protein 1 and domainsNallely García-Larragoiti, Young Chan Kim, César López-Camacho, et al.Journal of Thrombosis and Haemostasis : JTH|June 2, 2021
Television viewing, physical activity and venous thromboembolism risk: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) StudyJordan A Munger, Insu Koh, George Howard, et al.Journal of Thrombosis and Haemostasis : JTH|December 14, 2020
RetractionJournal of Thrombosis and Haemostasis : JTH|May 31, 2022
Pharmacological reduction of coagulation factor XI reduces macrophage accumulation and accelerates deep vein thrombosis resolution in a mouse model of venous thrombosisKelley R Jordan, Cory R Wyatt, Meghan E Fallon, et al.Journal of Thrombosis and Haemostasis : JTH|June 24, 2022
Practical considerations and consensus opinion for children's hospital-based inpatient hemostasis and thrombosis (HAT) consultative services: Communication from the ISTH SSC Subcommittee on Pediatric/Neonatal Thrombosis and HemostasisGary M Woods, Leslie Raffini, Leonardo R Brandão, et al.Journal of Thrombosis and Haemostasis : JTH|July 5, 2021
Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID-19 patientsBérangère S Joly, Michael Darmon, Charlotte Dekimpe, et al.Journal of Thrombosis and Haemostasis : JTH|January 28, 2020
An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia AMasahiro Takeyama, Keiji Nogami, Tomoko Matsumoto, et al.Journal of Thrombosis and Haemostasis : JTH|November 26, 2018
mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumorsC S Lewis, H Elnakat Thomas, M A Orr-Asman, et al.Pageof 650